Discontinued — last reported Q3 '23

Other Income & Expense

Net Unrealized Loss on Equity Securities

Vertex Pharmaceuticals Net Unrealized Loss on Equity Securities decreased by 157.8% to -$16.50M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 271.4%, from $9.63M to -$16.50M. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalLower is better
VolatilityVolatile
First reportedQ1 2022
Last reportedQ3 2023

How to read this metric

Higher losses indicate poor performance of the company's investment holdings or broader market downturns.

Detailed definition

This metric reflects the decrease in the fair market value of equity investments held by the company that have not yet b...

Peer comparison

Common for companies with large treasury or venture investment portfolios.

Metric ID: is_gild_net_unrealized_loss_on_equity_securities

Historical Data

7 periods
 Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$9.63M$9.63M$9.63M$9.63M$38.50M-$6.40M-$16.50M
QoQ Change—+0.0%+0.0%+0.0%+300.0%-116.6%-157.8%
YoY Change————+300.0%-166.5%-271.4%
Range-$16.50M – $38.50M
CAGR+43.2%
Avg YoY Growth-46.0%
Median YoY Growth-166.5%
Current Streak2 quarters decline

Frequently Asked Questions

What is Vertex Pharmaceuticals's net unrealized loss on equity securities?
Vertex Pharmaceuticals (VRTX) reported net unrealized loss on equity securities of -$16.50M in Q3 2025.
How has Vertex Pharmaceuticals's net unrealized loss on equity securities changed year-over-year?
Vertex Pharmaceuticals's net unrealized loss on equity securities decreased by 271.4% year-over-year, from $9.63M to -$16.50M.
What does net unrealized loss on equity securities mean?
Loss from the decrease in value of stock investments that have not been sold yet.